Literature DB >> 24491810

MEKK2 regulates focal adhesion stability and motility in invasive breast cancer cells.

Ahmed A Mirza1, Michael P Kahle1, Magdalene Ameka1, Edward M Campbell1, Bruce D Cuevas2.   

Abstract

MEK Kinase 2 (MEKK2) is a serine/threonine kinase that functions as a MAPK kinase kinase (MAP3K) to regulate activation of Mitogen-activated Protein Kinases (MAPKs). We recently have demonstrated that ablation of MEKK2 expression in invasive breast tumor cells dramatically inhibits xenograft metastasis, but the mechanism by which MEKK2 influences metastasis-related tumor cell function is unknown. In this study, we investigate MEKK2 function and demonstrate that silencing MEKK2 expression in breast tumor cell significantly enhances cell spread area and focal adhesion stability while reducing cell migration. We show that cell attachment to the matrix proteins fibronectin or Matrigel induces MEKK2 activation and localization to focal adhesions. Further, we reveal that MEKK2 ablation enhances focal adhesion size and frequency, thereby linking MEKK2 function to focal adhesion stability. Finally, we show that MEKK2 knockdown inhibits fibronectin-induced Extracellular Signal-Regulated Kinase 5 (ERK5) signaling and Focal Adhesion Kinase (FAK) autophosphorylation. Taken together, our results strongly support a role for MEKK2 as a regulator of signaling that modulates breast tumor cell spread area and migration through control of focal adhesion stability.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fibronectin; Focal adhesion; Kinase; MEKK2

Mesh:

Substances:

Year:  2014        PMID: 24491810      PMCID: PMC3960922          DOI: 10.1016/j.bbamcr.2014.01.029

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  25 in total

1.  Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways.

Authors:  James A Witowsky; Gary L Johnson
Journal:  J Biol Chem       Date:  2002-11-26       Impact factor: 5.157

2.  MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts.

Authors:  Bruce D Cuevas; Amy N Abell; James A Witowsky; Toshiaki Yujiri; Nancy Lassignal Johnson; Kamala Kesavan; Marti Ware; Peter L Jones; Scott A Weed; Roberta L DeBiasi; Yoshitomo Oka; Kenneth L Tyler; Gary L Johnson
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

3.  PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway.

Authors:  Kazuhiro Nakamura; Gary L Johnson
Journal:  J Biol Chem       Date:  2003-08-11       Impact factor: 5.157

Review 4.  Role of mitogen-activated protein kinase kinase kinases in signal integration.

Authors:  B D Cuevas; A N Abell; G L Johnson
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 5.  Integrin ligands at a glance.

Authors:  Jonathan D Humphries; Adam Byron; Martin J Humphries
Journal:  J Cell Sci       Date:  2006-10-01       Impact factor: 5.285

6.  Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation.

Authors:  Motozo Yamashita; Sai-Xia Ying; Gen-Mu Zhang; Cuiling Li; Steven Y Cheng; Chu-Xia Deng; Ying E Zhang
Journal:  Cell       Date:  2005-04-08       Impact factor: 41.582

7.  MEKK2 kinase association with 14-3-3 protein regulates activation of c-Jun N-terminal kinase.

Authors:  Adi E Matitau; Timothy V Gabor; R Montgomery Gill; Michael P Scheid
Journal:  J Biol Chem       Date:  2013-08-20       Impact factor: 5.157

Review 8.  MAP kinases and cell migration.

Authors:  Cai Huang; Ken Jacobson; Michael D Schaller
Journal:  J Cell Sci       Date:  2004-09-15       Impact factor: 5.285

9.  Chemical genetic analysis of the time course of signal transduction by JNK.

Authors:  Juan-Jose Ventura; Anette Hübner; Chao Zhang; Richard A Flavell; Kevan M Shokat; Roger J Davis
Journal:  Mol Cell       Date:  2006-03-03       Impact factor: 17.970

10.  Knockout of ERK5 causes multiple defects in placental and embryonic development.

Authors:  Lijun Yan; Julia Carr; Peter R Ashby; Victoria Murry-Tait; Calum Thompson; J Simon C Arthur
Journal:  BMC Dev Biol       Date:  2003-12-16       Impact factor: 1.978

View more
  14 in total

Review 1.  Oncogenic signaling of MEK5-ERK5.

Authors:  Van T Hoang; Thomas J Yan; Jane E Cavanaugh; Patrick T Flaherty; Barbara S Beckman; Matthew E Burow
Journal:  Cancer Lett       Date:  2017-01-30       Impact factor: 8.679

2.  Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).

Authors:  Syed Ahmad; Valentine R St Hilaire; Srinivasa R Dandepally; Gary L Johnson; Alfred L Williams; John E Scott
Journal:  Biochem Biophys Res Commun       Date:  2018-01-05       Impact factor: 3.575

3.  Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment.

Authors:  Donna M Sosnoski; Robert J Norgard; Cassidy D Grove; Shelby J Foster; Andrea M Mastro
Journal:  Clin Exp Metastasis       Date:  2015-03-08       Impact factor: 5.150

4.  Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast.

Authors:  Peng Sun; Zaixuan Zhong; Qianyi Lu; Mei Li; Xue Chao; Dan Chen; Wenyan Hu; Rongzhen Luo; Jiehua He
Journal:  Mod Pathol       Date:  2020-05-01       Impact factor: 7.842

5.  Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.

Authors:  Syed Ahmad; Gary L Johnson; John E Scott
Journal:  Biochem Biophys Res Commun       Date:  2015-06-06       Impact factor: 3.575

6.  MEKK2 regulates paxillin ubiquitylation and localization in MDA-MB 231 breast cancer cells.

Authors:  Magdalene Ameka; Michael P Kahle; Mathew Perez-Neut; Saverio Gentile; Ahmed A Mirza; Bruce D Cuevas
Journal:  Biochem J       Date:  2014-11-15       Impact factor: 3.857

Review 7.  Dynamic self-guiding analysis of Alzheimer's disease.

Authors:  Alexei Kurakin; Dale E Bredesen
Journal:  Oncotarget       Date:  2015-06-10

8.  miR-302a inhibits human HepG2 and SMMC-7721 cells proliferation and promotes apoptosis by targeting MAP3K2 and PBX3.

Authors:  Meng Wang; Guoyue Lv; Chao Jiang; Shuli Xie; Guangyi Wang
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

9.  Interaction with the Paxillin LD1 Motif Relieves MEKK2 Auto-inhibition.

Authors:  Michael P Kahle; Bruce D Cuevas
Journal:  J Mol Signal       Date:  2015-10-16

10.  MAP3K2 augments Th1 cell differentiation via IL-18 to promote T cell-mediated colitis.

Authors:  Ningbo Wu; Dongping Chen; Hongxiang Sun; Jianmei Tan; Yao Zhang; Tianyu Zhang; Yuheng Han; Hongzhi Liu; Xinxing Ouyang; Xiao-Dong Yang; Xiaoyin Niu; Jie Zhong; Zhengting Wang; Bing Su
Journal:  Sci China Life Sci       Date:  2020-07-28       Impact factor: 6.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.